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Early Predictive Biomarkers for Lesion After Transient
Cerebral Ischemia
Carole Berthet, PhD*; Hongxia Lei, PhD*; Rolf Gruetter, PhD; Lorenz Hirt, MD
Background and Purpose—Despite the improving imaging techniques, it remains challenging to predict the outcome
early after transient cerebral ischemia. The aim of this study was thus to identify early metabolic biomarkers for
outcome prediction.
Methods—We modeled transient ischemic attacks and strokes in mice. Using high-field MR spectroscopy, we correlated
early changes in the neurochemical profile of the ischemic striatum with histopathologic alterations at a later time point.
Results—A significant increase in glutamine was measured between 3 hours and 8 hours after all ischemic events followed
by reperfusion independently of the outcome and can thus be considered as an indicator of recent transient ischemia.
On the other hand, a reduction of the score obtained by summing the concentrations of N-acetyl aspartate, glutamate,
and taurine was a good predictor of an irreversible lesion as early as 3 hours after ischemia.
Conclusions—We identified biomarkers of reversible and irreversible ischemic damage, which can be used in an early
predictive evaluation of stroke outcome. (Stroke. 2011;42:799-805.)
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The course of ischemic episodes is very variable and it isdifficult to predict the outcome of an individual patient
early after ischemia and particularly early after reperfusion. A
better prediction of the outcome at early time points would
greatly facilitate clinical decisions. Moreover, this would help
to distinguish transient ischemic attacks (TIAs) from stroke,
refine patient selection for neuroprotection trials, and even-
tually help to identify patients more likely to benefit from
future neuroprotective approaches.
Several cerebral imaging techniques are available for the
diagnosis and management of patients with stroke.1 At late
time points, the established lesion can be visualized both by
T2-weighted images and CT. At early time points, before
reperfusion, perfusion CT or perfusion-weighted MR images
are used to measure perfusion and allow an estimation of
damaged tissue and tissue at risk.2 Diffusion-weighted MR
images (DWI), and to some extent diffusion tensor imaging,
monitor disturbances of ion homeostasis, water distribution,
and tissue microstructure. The apparent diffusion coefficient
(ADC) measured from DWI decreases immediately after the
onset of ischemia and its decrease is proportional to the
severity of ischemia.3 A combination of DWI and perfusion-
weighted MR imaging techniques is used to detect tissue at
risk where perfusion is decreased but water diffusion is still
normal.3 These techniques convey a good spatial resolution,
are highly sensitive, and give information on the localization
and extent of the lesion, but the estimation of the severity of
ischemia is not very reliable insomuch as DWI hyperintensi-
ties are often reversible.4 Moreover, detection of only half of
the TIAs is possible even when using a combination of DWI
and perfusion-weighted imaging.5 Similarly, in animal mod-
els, transient ischemia cannot be detected using T2-weighted
images, perfusion-weighted images, nor DWIs during the
first hours after reperfusion.6
Another NMR technique, MR spectroscopy (MRS), can
give information on the severity of ischemic injury by
measuring metabolites after cerebral ischemia. In particular, a
decrease in N-acetyl-aspartate (NAA) has been shown to
correlate with neuronal loss,7 which was expanded to predict
outcome after stroke8–10 and traumatic brain injury.10 Recent
studies in ischemic mice or patients with traumatic brain
injury11,12 showed important metabolite concentration
changes in areas or at time points (between 3 and 24 hours)
in which no abnormality could be detected by MRI, suggest-
ing that MRS could detect early tissue damage or compro-
mised cell function. Therefore, the aim of the present study
was to identify neurochemical markers for transient cerebral
ischemia and outcome prediction at very early time points
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after reperfusion when neither T2 hyperintensities nor abnor-
mal water diffusion are detectable by MRI.
Methods
All animal experiments were conducted in accordance with the
guidelines of and with approval of the cantonal veterinary office.
Transient Middle Cerebral Artery Occlusion in
the Mouse
For MR studies, 29 male ICR-CD1 mice (20 to 33 g; Charles River,
L’Arbresle, France) underwent transient middle cerebral artery
occlusion (tMCAO) as described previously.12 Briefly, mice were
anesthetized and maintained under 1.5% to 2% isoflurane in 30%
oxygen and 70% nitrous oxide using a face mask. At 0 hour,
ischemia was induced by inserting a silicone-coated nylon filament
(diameter: 0.17 mm; Doccol Co, Redlands, CA) through the left
common carotid artery into the internal carotid artery. The filament
was withdrawn after 10 minutes allowing reperfusion. Regional
cerebral blood flow was measured throughout the entire operation by
a laser-Doppler flowmetry (Periflux 5000; Perimed) with a flexible
probe fixed on the skull, 2 mm posteriorly and 6 mm laterally from
the bregma. The average regional cerebral blood flow of included
mice was 15%5% (no lesion) and 14%4% (lesion) of the
baseline level during ischemia and 74%16% (no lesion) and
74%20% (lesion) of the baseline after reperfusion. Throughout
surgery and until awaking, the rectal temperature was maintained at
370.5°C with a temperature control unit (FHC Inc).
Mice were euthanized 30 hours after ischemia. Among these mice,
4 were excluded due to unsatisfactory ischemia or spectral quality (2
Figure 1. The 2 10-minute middle cere-
bral artery occlusion (MCAO) subgroups
have different MR spectra at all mea-
sured time points. Evolution of MR spec-
tra over time and T2-weighted images at
24 hours. Each column corresponds to a
representative mouse from each group
(sham, TIA, minor stroke). Each row
shows typical measurements of 1H-MR
spectra at 3 hours (A), 8 hours (B), and
24 hours (C) or T2-weighted images at
24 hours after ischemia (D) of the same
mouse. All spectra were scaled relative
to the heights of the phosphocreatine
creatine and macromolecule peaks in
the spectrum of the sham operated
group at 3 hours (A). Arrows show the
apparent changes in the spectra from
both 10-minute tMCAO groups com-
pared with sham-operated animals. Cr
indicates creatine; GIn, glutamine; Glu,
glutamate; GPC, glycerophosphocholine;
Lac, lactate; Mac, macromolecules;
myo-Ins, myo-inositiol; PCho, phospho-
choline; PCr, phosphocreatine; Tau, tau-
rine; T2WI, T2-weighted images.
Figure 2. Evolution over time of some
metabolites involved in the developing
lesion after ischemia. The moderate
stroke group is described in a recent
publication.12 (A) Glutamine (Gln), (B) glu-
tamate (Glu), (C) taurine (Tau), (D)
N-acetyl aspartateglutamatetaurine
(NAAGluTau). Error bars reflect SD.
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mice) and 9 were used for histological characterization at 3 hours, 8
hours, and 24 hours after ischemia. In addition, 7 mice (24 to 34 g)
of the sham group underwent the same procedure without any artery
ligation.
Neurological Deficits
Mice were observed before euthanasia to evaluate their neurological
deficit. Their neuroscore was graded as previously described13 (0, no
observable neurological deficit; 1, failure to extend the right fore-
paw; 2, circling to the contralateral side; and 3, loss of walking or
righting reflex).
Determination of Ischemic Lesion Volumes
Animals were euthanized by intracardiac paraformaldehyde (4% in
phosphate-buffered saline) perfusion. Brains were postfixed over-
night in 4% paraformaldehyde and cryoprotected in 30% sucrose for
48 hours before freezing. 20-m-thick, 700-m distant, coronal
cryostat sections were prepared. Lesion size was determined on
cresyl violet-stained sections and MR images as described
previously.12
In Vivo MR Studies
MR studies were carried out in a horizontal, 14.1-T/26-cm magnet
(Magnex Scientific, Abingdon, UK) with a 12-cm inner-diameter
gradient (400 mT/m in 200 s, minimized eddy currents) interfaced
to a DirectDrive console (Varian Inc, Palo Alto, CA). A home-built
quadrature surface coil with 2 geometrically decoupled single turn
loops (12 mm inner diameter) resonating at 600-MHz radiofrequency
was used for radiofrequency transmission and reception at 14.1-T as
described previously.12
MR Imaging
Multislice (200.6-mm slices) T2-weighted coronal images were
acquired using the fast spin echo technique14 with effective echo
time TEeff50 ms and repetition time TR6000 ms to locate the
volume of interest in the left striatum and evaluate the development
of ischemic lesions at 24 hours postischemia.
Four of the 10-minute middle cerebral artery occlusion mice were
randomly selected and underwent DWI measurement at 3 hours
postischemia. Diffusion tensor images were acquired for calculating
the ADC maps using segmented (4 shots) semiadiabatic double spin
echo echoplanar imaging15 (ROPE2315 mm2, 12864 data
matrix) with additional diffusion gradients (Gdiff21 G/cm, 3ms,
20 ms, and giving a b-value of 1079 s/mm2) along 7 dimensions.
Five of 0.8-mm-thickness contiguous coronal slices were acquired
with TE/TR42.5/2000 ms and 7 averages. Nyquist ghosts were
minimized by adopting a previously described “negative readout
gradient” strategy.16 The total scan time was 17 minutes.
MR Spectroscopy
Field inhomogeneities were adjusted over the volume of interest
using the echoplanar version of FASTMAP17 and resulted in water
line widths within 30 Hz for 6 to 8 L volumes. Localized 1H
nuclear MR spectra were obtained for each animal at 3 hours, 8
hours, and 24 hours using the SPECIAL technique18 (echo/repetition
time2.8/4000 ms, 240 to 320 averages) in combination with outer
volume suppression and VAPOR water suppression,19 resulted in the
acquired MR spectra with satisfactory signal-to-noise ratios (153)
and excellent metabolic line widths (184 Hz, 10 to 30 Hz).
Quantification
ADC maps were derived from the acquired diffusion tensor images
for 2 regions of interest, that is, ipsilateral and contralateral striatal
tissue using Matlab.
The in vivo 1H-MR spectra were processed as described in Lei et
al.12 Absolute quantification was obtained using a linear combination
analysis method, Linear Combination of Model Spectra (LC-
Model)20 assuming 80% brain water content (100% visibility of
water signal and 55.5 mol/L molarities).
Statistics
All data are presented as meanSD, except neurological scores
(median [minimum, maximum]). Significance was set as P0.05
using the Mann-Whitney test to compare lesion size measured by
MRI and histologically, the Kruskal-Wallis test followed by Dunn
multiple-comparison test for neuroscore comparisons, the Student t
test for ADC measurements, and Pearson r test to correlate final
lesion size to metabolite concentrations (GraphPad Prizm 5).
Results
Characterization of Degrees of Ischemic Severity
in Mice
The design of the present study was to compare animals
below and above the threshold for irreversible ischemic
Figure 3. Evolution over time of metabo-
lites widely used in predicting lesion
after ischemia. *The moderate stroke
group is described in a recent publica-
tion.12 (A) lactate (Lac), (B) N-acetyl
aspartate (NAA). Error bars reflect SD.
Figure 4. A combination of 4 metabolites at 3 hours allows a
very good separation among the 4 groups. Glutamine (Gln) is
increased in all ischemic conditions with reperfusion indepen-
dently of the outcome. A combined score obtained by adding
the concentrations of N-acetyl-aspartate, glutamate, and taurine
(NAAGluTau) at 3 hours identifies the animals that will
develop a lesion later on. *The moderate stroke group is taken
from our recent publication.12 The scatter plot of NAAGluTau
versus Gln allows very good separation among the 4 experi-
mental groups.
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lesions to find biomarkers for outcome prediction. We no-
ticed that in our model, 10 minutes of ischemia produced
small striatal lesions in half the mice only, indicating that this
ischemia duration lies at this threshold. These mice were
divided into 2 groups depending on the presence (n7) or
absence (n10) of a lesion on T2-weighted MR images at
24 hours. These mice were compared with sham-operated
and 30-minute tMCAO mice. All animals were euthanized
30 hours after ischemia onset for histology and lesion size
determination (Supplemental Figure I, available at
http://stroke.ahajournals.org). Small lesions were detected 30
hours after 10 minutes tMCAO (3.32.9 mm3) in the lesion
10-minute tMCAO group consistent with the lesion size
measured at 24 hours on MR images of 8.33.5 mm3. The
slight difference in lesion size between MRI and Nissl
staining (P0.026, 2-tailed Mann-Whitney test) probably
results from a small overestimation of the lesion size by MRI
due to edema or to the 6-hour difference between these
measurements. It is consistent with similar previously ob-
served differences.12
The neuroscore determined at 30 hours was not signifi-
cantly different between no lesion 10-minute tMCAO (0 [0 to
0.5]) and lesion 10-minute tMCAO (0 [0 to 1]) but between
both of them and 30-minute tMCAO (1 [0.5 to 2]; P0.01
and P0.05, respectively, using Kruskal-Wallis followed by
Dunn multiple comparison test). There was complete recov-
ery of the neurological deficit at 30 hours in almost all
animals in our “no lesion” tMCAO group and no lesion was
detected by MRI. The short ischemia in this group therefore
corresponds to TIAs according to the new definition proposed
by Easton et al.21 We thus called it the “TIA group.”
Similarly, we called the 10-minute tMCAO group with lesion
the “minor stroke” group and the 30-minute tMCAO “mod-
erate stroke” group.
MR Assessments of Metabolic Evolution
After Ischemia
At 3 hours after transient ischemia, there was no detectable
signal change in any group on either T2-weighted images or
on ADC maps (6.820.19104 mm2/s in ipsilateral stria-
tum versus 6.850.24104 mm2/s in contralateral striatum
with P0.80 by paired Student t test). On the contrary,
several changes were apparent in the spectra of both TIA and
minor stroke groups (Figure 1) as early as 3 hours after
ischemia: increased glutamine was observed in both groups,
which was accompanied by a decrease in glutamate only in
the minor stroke group. The metabolic profile of the sham-
operated mice did not vary. In mice that were developing a
lesion, additional metabolite changes appeared at 8 hours
(increased lactate) and 24 hours (decreased NAA and myo-
inositol), whereas the neurochemical profile of the TIA group
almost normalized at 24 hours.
Neurochemical Changes Can Be Used to
Characterize the Severity of Transient
Ischemic Insults
The visually noticeable MR spectra changes were confirmed
by quantitative measurements of the neurochemical profiles
(Figures 2 and 3; Supplemental Figure II), which further
revealed additional changes. The increase in glutamine 3
hours after ischemia was a common hallmark of all transient
ischemic episodes regardless of the duration. It returned to
basal levels more quickly in the absence of a lesion (Figure
2A; Supplemental Figure II).12 On the other hand, glutamate,
NAA, and taurine were significantly decreased as early as 3
hours after the insult only in animals with irreversible damage
(Figures 2B–C and 3B; Supplemental Figure II). We summed
the concentrations of these 3 metabolites and noted that this
composite score separated mice that will develop a lesion or
not (Figure 2D), whereas lactate or NAA concentrations were
unable to separate them before 8 hours (Figure 3A–B).
Figure 5. The cumulative score of N-acetyl-
aspartateglutamatetaurine is in good correlation with the
final lesion size. Correlation of selected metabolites at each time
point with the ischemic lesion at 24 hours. At 3 hours, only the
combination of N-acetyl-aspartateglutamatetaurine
(NAAGluTau) allows a good correlation (calculated with
Pearson r test) with final lesion size, whereas the other correla-
tions (lactate, NAA) get better with time. *The moderate stroke
group is taken from our recent publication.12 (A) NAAGluTau
at 3 hours, (B) lactate (Lac) at 3 hours, (C) NAA at 3 hours, (D)
summary of the correlation coefficients of NAAGluTau, Lac
and NAA at 3, 8, and 24 hours in absolute values. The “R”
stands for the absolute value from Pearson r test.
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Scatterplotting the NAAglutamatetaurine score against
the glutamine concentration at 3 hours (Figure 4) allowed
excellent separation of the 4 conditions with nearly no
overlap, especially between the TIA and stroke groups. After
3 hours of permanent ischemia (Supplemental Figure III), the
metabolism is different, showing a decrease of glutamine
instead of an increase. However, the composite score of
NAAglutamatetaurine is also decreased, indicating that a
lesion will develop. It is thus also a good predictor in the
absence of reperfusion.
Neurochemical Changes Predict Ischemic
Lesion Size
The correlations between lactate or NAA at 3 hours and
MRI lesions at 24 hours (R0.73 and R0.77, respec-
tively, absolute values from Pearson r test; Figure 5B–C)
were found to be less precise than the correlation between
NAAglutamatetaurine at 3 hours and the resulting lesion
size at 24 hours (R0.90; Figure 5A). Even if, at later time
points, the prediction of lesion size with lactate (R0.76 at 8
hours and R0.78 at 24 hours; Figure 5D) and NAA (R0.76
at 8 hours and R0.95 at 24 hours; Figure 5D) becomes more
accurate, the sum of NAAglutamatetaurine remains the
best predictor up to 8 hours (R0.87; Figure 5D) and is
similar to NAA at 24 hours (R0.97; Figure 5D).
Discussion
By measuring 19 neurochemical constituents in the mouse
striatum 3 and 8 hours after cerebral ischemia of varying
intensity, we have shown that 1H MRS highlights metabolic
changes reflecting a recent transient ischemia and predicts the
outcome at 24 hours. Ischemia triggered a transient increase
in glutamine after reperfusion independent of its severity,
whereas irreversibly damaged tissue was characterized by a
significant decrease in NAA, glutamate, and taurine indepen-
dently of reperfusion. To our knowledge, this is the first time
that predictive biomarkers of cerebral ischemia have been
described at an early time point when no abnormality can be
detected with standard and widely used clinical MRI
techniques.6,22
It is remarkable to see that the only metabolic change
common to all ischemic conditions after reperfusion is
increased glutamine, which we previously hypothesized to
result from the transformation of excitotoxic glutamate by
astrocytes after restoration of energy supplies.12 Our obser-
vation of reduced glutamine levels 3 hours after permanent
ischemia (Supplemental Figure III) supports this hypothesis.
Thus, the elevated glutamine can be used as a biomarker of
reperfused ischemia at an early time point.
Of the more established metabolic changes after ischemia,
it is well known that the NAA concentration correlates well
with observed ischemic lesion size and extent of neuronal
death.8–10,23,24 However, this cannot be reliably correlated
earlier than 8 to 24 hours after ischemia (Figure 4) probably
because neuronal death is a gradual process after mild to
moderate ischemia. In addition to NAA, increased lactate is a
hallmark of ischemia23,25,26 that has been described in patients
with TIAs.27,28 However, the early measurements in the
present study (showing no change in lactate concentration
after 10 minutes middle cerebral artery occlusion) suggest
that lactate may not reliably identify ischemic episodes or
predict ischemic outcome. The difference in lactate concen-
trations between patients with TIA and our 10-minute ische-
mic mice might be due to the time of 1H MRS measurements,
which were performed 1 day after the attack in the human
studies. Moreover, the lactate profile is complex with 2
episodes of lactate accumulation,29 and probably lactate
content at early stages does not reliably predict the outcome.
In addition, 2 further metabolites mainly linked to neuronal
metabolism and strongly involved in ischemia,8–10,23,24,30
glutamate and taurine, decreased in the minor stroke group.
The glutamate decrease is consistent with the well-known
glutamate release from neurons during ischemia, which is
then taken up by astrocytes and either transformed to glu-
tamine or oxidized after reperfusion.31 On the other hand,
taurine is thought to be neuroprotective by both acting on
osmoregulation32 and neuromodulation.33 Recently, Saran-
saari and Oja30 have shown that taurine release in ischemia
is modulated by glutamate receptors, which may explain
the correlation between taurine decrease and severity of
ischemia. Importantly, the final ischemic lesion stands in
excellent correlation with our cumulative score of
NAAglutamatetaurine not only at 24 hours, but also as
early as 3 hours and 8 hours (Figure 5). Therefore, this
combination score is well adapted for the prediction of
ischemia severity.
The highly predictive power of these biomarkers in animal
models now needs testing in human patients with TIA and
Figure 6. MRS is the only noninvasive diagnostic method able to determine if cerebral tissue has suffered from ischemia and to predict
its outcome between 1 hour and 8 hours after ischemia. Green (short ischemia without lesion) and orange bars (short ischemia with
lesion) represent the period when an abnormality can be detected with the corresponding technique. Lighter bars represent expected
detection in need to be tested. CBF indicates cerebral blood flow; fMRI, functional MRI; Gln, glutamine; Glu, glutamate; PWI, perfusion-
weighted imaging; T2WI, T2-weighted images; Tau, taurine.
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stroke. Indeed, our goal is to test if MRS biomarkers could be
used for early diagnosis for treatment optimization. The
distinction between TIA and stroke is an important but
difficult question based on the definition of TIA. The biomar-
kers described in this study could help distinguish between
TIA and stroke only if we use the new definition of TIA.21 In
any case, both patients with TIA and those with stroke have
to be observed in the hospital. The importance of the
biomarkers will be to help determine if a patient with an acute
neurological deficit will later develop a lesion and thus if
neuroprotective treatment is needed. Moreover, the observa-
tion of glutamine increase in patients with TIA can help
determine which areas had a lack of perfusion. The advantage
of MRS compared with routinely used imaging techniques34
is its capacity to identify recent ischemic events and predict
outcome in the first hours after reperfusion, at a time when
none of the other techniques detect any abnormality (Figure
6) and where diagnostic blood biomarkers are less precise.35
In conclusion, the ability to identify ischemic damage and
predict the outcome (neuronal loss or recovery) based on
metabolite concentrations between 3 and 8 hours after ische-
mia opens exciting perspectives for stroke diagnosis and
treatment. Given that the biomarkers described in this study
can also be measured in humans using clinical 3-T MR
equipment,36 1H-MRS could thus provide critical information
for the evaluation and diagnosis in patients with stroke and
TIA.
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